2. Academic Validation
  3. Emerging modes-of-action in drug discovery

Emerging modes-of-action in drug discovery

  • Medchemcomm. 2019 Jun 25;10(9):1550-1568. doi: 10.1039/c9md00263d.
Eric Valeur 1,  Frank Narjes 2,  Christian Ottmann 3 4,  Alleyn T Plowright 5
Affiliations

Affiliations

  • 1 Medicinal Chemistry , Research and Early Development, Cardiovascular, Renal & Metabolism , BioPharmaceuticals R&D , AstraZeneca, Gothenburg , 43183 Mölndal , Sweden . Email: evaleur@yahoo.fr.
  • 2 Medicinal Chemistry , Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA) , BioPharmaceuticals R&D , AstraZeneca, Gothenburg , 43183 Mölndal , Sweden.
  • 3 Department of Biomedical Engineering and Institute for Complex Molecular Systems , Technische Universiteit Eindhoven , Den Dolech 2 , 5612 , AZ , Eindhoven , the Netherlands.
  • 4 Department of Chemistry , University of Duisburg-Essen , Universitätsstraße 7 , 45117 , Essen , Germany.
  • 5 Integrated Drug Discovery , Sanofi-Aventis Deutschland GmbH , Industriepark Höchst , D-65926 Frankfurt am Main , Germany.
PMID: 31673315 DOI: 10.1039/c9md00263d
Abstract

An increasing focus on complex biology to cure diseases rather than merely treat symptoms has transformed how drug discovery can be approached. Instead of activating or blocking protein function, a growing repertoire of drug modalities can be leveraged or engineered to hijack cellular processes, such as translational regulation or degradation mechanisms. Drug hunters can therefore access a wider arsenal of modes-of-action to modulate biological processes and this review summarises these emerging strategies by highlighting the most representative examples of these approaches.

Figures